New Radiation Implant Slashes Tumor Return in Brain Metastases

A new way of delivering radiation during brain surgery kept tumors from coming back far more often — and was linked to significantly longer survival — than the current standard treatment, according to a phase 3 clinical trial published in the Journal of Clinical Oncology.

The therapy, called GammaTile, is a small, flexible implant about the size of a postage stamp. A surgeon places it directly into the space left behind after removing a brain tumor. Made of a collagen material the body absorbs over time, it holds four tiny radiation seeds that release a low, steady dose of radiation for several weeks — starting the moment surgery ends.

That's different from the usual approach, in which patients heal from surgery first, then return separately, typically a few weeks later, for a course of stereotactic radiation therapy (SRT) delivered from outside the body.

What the Study Found

The trial, called ROADS, followed 230 patients at 32 medical centers who had surgery for a newly diagnosed brain metastasis — a tumor that started elsewhere in the body, often in the lung, breast or from melanoma, and spread to the brain. After surgery, patients were randomly assigned to get either the GammaTile implant or standard SRT.

One year later, the tumor had returned in the same spot in just 1.3% of patients who got GammaTile, compared with 15.4% of those who got standard radiation. That means tumor control held in 98.7% of GammaTile patients, versus 84.6% with standard treatment.

Patients who received GammaTile also lived substantially longer: median survival was 42.5 months, compared with 17.6 months for those who received standard radiation — a difference of nearly two years.

Side effects were similar between the two groups. Serious side effects occurred in about 1 in 5 patients either way, and measures of daily functioning and quality of life were comparable.

What This Means for You

If you or someone you love is facing surgery for a brain metastasis, this research suggests GammaTile may be worth asking about. Because the radiation is built into the surgery itself, there's no separate treatment appointment to schedule afterward — notably, in this trial, about 1 in 6 patients assigned to standard radiation never ended up completing it.

It's important to know what this trial did test, and didn't: it applies to patients whose brain metastasis can be surgically removed, not to those treated with radiation alone. And while the results are striking, this is one trial; more real-world experience over time will help confirm how lasting the benefit is.

GammaTile is already FDA-cleared and in use at more than 150 U.S. cancer centers, so it isn't experimental or something you'd need to find through a clinical trial. But not every hospital offers it, and not everyone is a candidate.

Questions to ask your care team: Is my brain metastasis one that's typically treated with surgery? Does this center offer GammaTile, or can I get a referral somewhere that does? What would recovery look like with GammaTile compared with standard radiation?

"Standard-of-care treatment for this disease has always focused on controlling the tumor in the brain so patients can get back to fighting their primary cancer, and [GammaTile] does that more effectively than existing treatment options," said Dr. Jeffrey Weinberg, a professor of neurosurgery at MD Anderson Cancer Center and the trial's co-lead investigator.

Reference

1. Weinberg JS, Imber BS, Beckham TH, et al. Surgery and tile-based radiation therapy versus surgery and stereotactic radiation for newly diagnosed brain metastases (ROADS): a randomized, open-label, phase 3 trial. J Clin Oncol. Published online September 2026. doi:10.1200/JCO-26-01894

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.